Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Oxidoreductase
Reexamination Certificate
2006-11-17
2010-06-08
Pak, Yong D (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Oxidoreductase
C435S004000, C435S006120, C435S025000, C435S069100, C435S071100, C435S252300, C435S320100, C435S440000, C536S023200
Reexamination Certificate
active
07732177
ABSTRACT:
The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.
REFERENCES:
patent: 5766897 (1998-06-01), Braxton
patent: 2003/0235575 (2003-12-01), Matzuk et al.
patent: WO 2005/040428 (2005-05-01), None
Branden et al. Introduction to Protein Structure, Garland Publishing Inc., New York, p. 247, 1991.
Sarkar, S. N. And Sen, G. C.,Methods: A Companion to Methods in Enzymology 15:233-242, 1998.
Sarkar S.N. et al., “The Nature of the Catalytic Domain of 2′-5′-Oligoadenylate Synthetases,” Journal of Biological Chemistry, American Society of Biochemical Biologists, Birmingham, U.S., vol. 274, No. 36, Sep. 3, 1999, p. 25535-25542, XP002326605.
Ghosh, Arundhati, et al., “Enzymatic Activity of 2′-5′-Oligoadenylate Synthetase is impaired by Specific Mutations that Affect Oligomerization of the Protein,” Journal of Biological Chemistry, vol. 272, No. 52, Dec. 26, 1997, p. 3320-33226, XP002444631.
Justesen, J., et al., “Gene Structure and Function of the 2′-5′-Oligoadenylate Synthetase Family,” CMLS Cellularu and Molecular Life Sciences, Birkhauser Verlag, Heidelberg, DE, vol. 57, No. 11, Oct. 2000, p. 1593-1612, XP001157584.
Torshin, Ivan, Y., “Three-Dimensional Models of Human ′2-′5-Oligoadenylate Synthetases: a New Computational Method for Reconstructing an Enzyme Assembly,” Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, Jul. 2005, vol. 11, No. 7, Jul. 2005. p. BR235-BR247, XP002444632.
Rysher, H.J. et al., “Histones and Basic Polyamino Acids Stimulate the Uptake of Albumin by Tumor Cells in Culture,” Science, New York, N.Y., Oct. 22, 1965, vol. 150, No. 695, p. 501-503, XP002444633.
Delgado, C. et al., “The Uses and Properties of PEG-Linked Proteins,” Critical Reviews in Therapeutic Drug carrier Systems, vol. 9, No. 3/4, 1992, p. 249-304, XP002930070.
Branum Mark
Iadonato Shawn P.
Magness Charles L.
McVean Maralee
Scherer Christina
Illumigen Biosciences Inc.
K&L Gates LLP
Pak Yong D
LandOfFree
Oligoadenylate Synthetase (OAS) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligoadenylate Synthetase (OAS), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligoadenylate Synthetase (OAS) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214286